Agenus shares are trading lower after the company announced the FDA discouraged an accelerated approval pathway at the end-of-Phase 2 meeting.
Portfolio Pulse from Benzinga Newsdesk
Agenus shares are trading lower following the announcement of results from its end-of-Phase 2 meeting with the FDA regarding its immunotherapy combination for colorectal cancer treatment.
July 18, 2024 | 11:53 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Agenus shares are trading lower after the company announced the results of its end-of-Phase 2 meeting with the FDA for its immunotherapy combination targeting colorectal cancer.
The announcement of the FDA meeting results likely raised concerns among investors about the future prospects of Agenus' immunotherapy combination, leading to a decline in share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100